Skip to content
← Index board

Health Optimization Index

MK-677 (Ibutamoren)

Nick’s assessment
Experimental
Research evidence
C, mixed evidence
Attention
16.7 / 100▲ Rising this week
4.9/ 10

BioHarmony score

MK-677 (ibutamoren) is an oral, once-daily growth-hormone secretagogue that raises IGF-1 by about 50 to 97 percent and adds roughly 1.1 kg of fat-free mass, per the Nass 2008 two-year trial, but it also raises fasting glucose and never won FDA approval.

Read the full report Benefits, risks and practical guidance.

Read Nick’s assessment Why it earned this rating

MK-677 sits at a 4.5–5.0/10, Neutral score because it is the best-evidenced growth-hormone secretagogue you can name and still not a clear win, which is an unusual place to land. The practical read: if you want oral convenience, deeper sleep, and lean-mass support, and you genuinely accept a certain glucose cost plus a cardiac caveat, it is a reasonable monitored experiment on verified product. If you are chasing proven strength, function, or longevity, the data actively argues against it, and a cleaner path exists. The score is justified because a strong evidence base full of negative results is exactly that, strong and discouraging at the same time. Merck developed MK-677 for years and never brought it to market. Despite evidence of target engagement, it was ineffective at slowing the progression of Alzheimer disease, the cleanest sign that raising IGF-1 is not the same as helping. Sevigny 2008

✅ Best for: Experienced users who value an oral, once-daily option over injections and will not miss the needle. People whose main goals are deeper sleep and lean-mass support rather than maximal strength, since the strength evidence is absent. Older adults with lower baseline growth hormone, who tend to respond more on the hormone markers. Anyone with clean fasting glucose and no cardiac history who will actually track glucose, HbA1c, and IGF-1 on a schedule. Users who can source third-party-tested material and verify identity, given documented mislabeling.

❌ Avoid if: You have diabetes, pre-diabetes, or metabolic syndrome, because MK-677 reliably worsens glucose control. You have heart failure or significant cardiac disease, given the congestive-heart-failure signal that halted a trial and the fluid-retaining mechanism. You have active or prior cancer, since IGF-1 is mitogenic and chronically raising it is a theoretical tumor-promotion risk. You compete in tested sport, since it is banned at all times under WADA category S2. You cannot verify source quality, because grey-market products are frequently mislabeled and sometimes contain other unapproved drugs entirely.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on MK-677 (Ibutamoren)
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 21, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.